Clinical Trial Update: Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AK104 plus chemotherapy and recombinant human adenovirus 5 injection for recurrent cervical cancer; the study is currently recruiting t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• Chemotherapy (chemotherapy)
• Recombinant Human Adenovirus 5 Injection

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Cervical Cancer Recurrent | Phase 2 | Status: RECRUITING